ATryn Available for Patients with Hereditary Antithrombin Deficiency, a Rare Blood Clotting Disorder

ClotCare: Blood Clots, Stroke, Heart Attack

Wednesday, October 30, 2024

Home | DVT/PE | Blood Clots | Coumadin/Warfarin | New Patients | Self Testing | Email List | Donate

Pick a Topic: Home New Postings Patient Postings Clinician Postings Join Our Email List Useful Web Links CE Opportunities Training Programs Guidelines DVT & PE Stories Editorial Board Financial Support About ClotCare DVT Coalition Contact Us Find info on a: Specific Medicine or Treatment Type of Medicine or Treatment Condition or Medical Procedure Lab Test Procedure Management Issue ClotCare complies with the HONcode standard for trustworthy health information: verify here. ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.	ATryn Available for Patients with Hereditary Antithrombin Deficiency, a Rare Blood Clotting Disorder Press Release from Lundbeck, Inc. May, 2009 Lundbeck Inc. offers recombinant antithrombin treatment option May 6, 2009 - Lundbeck Inc., a wholly owned subsidiary of H. Lundbeck A/S in Denmark (LUN: Copenhagen Stock Exchange), announced today that ATryn® (Antithrombin [Recombinant]) is now available in the United States. In February 2009, the U.S. Food and Drug Administration (FDA) granted marketing approval of ATryn, developed through recombinant technology, for the prevention of peri-operative and peri-partum thromboembolic events in patients with hereditary antithrombin deficiency (HD AT), a rare and potentially fatal blood clotting disorder. ATryn is not indicated for treatment of thromboembolic events in hereditary antithrombin deficient patients. The product is marketed in the U.S. by Lundbeck Inc. and manufactured by GTC Biotherapeutics, Inc. (NASDAQ: GTCB).... Click here to download the complete press release from Lundbeck, Inc. Click here to go to the Atryn website.	Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org. ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters. New Postings: Click here to view full list of new postings
ClotCare Home \| New Postings \| Patient Postings \| Clinician Postings \| Join Our Email List \| Useful Web Links CE Opportunities \| Training Programs \| DVT & PE Stories \| Editorial Board \| Financial Support About ClotCare \| DVT Coalition \| Donate to ClotCare \| Contact Us
Key topics discussed on ClotCare include: Blood Clots \| Deep Vein Thrombosis (DVT) \| Pulmonary Embolism (PE) \| Atrial Fibrillation (A. Fib or AF) \| Heart Attack \| Stroke \| Transient Ischemic Attack (TIA) \| Mini Stroke \| Bleeding Complications \| Vascular Surgery \| Surgical Blood Clot Removal \| Warfarin \| Coumadin \| Lovenox \| Low Molecular Weight Heparin (LMWH) \| Heparin \| Anticoagulants \| Plavix \| Aspirin \| Antiplatelets \| Blood Thinners
Copyright 2000-2018 by ClotCare. All rights reserved. Terms, Conditions, & Privacy \| Image Copyright Information 19260 Stone Oak Parkway, Suite 101 \| San Antonio, TX 78258 \| 210-860-0487 Send comments to webmaster@clotcare.org. Wednesday, October 30, 2024